Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381249229> ?p ?o ?g. }
- W4381249229 endingPage "1747" @default.
- W4381249229 startingPage "1747" @default.
- W4381249229 abstract "Upregulation of cyclooxygenase (COX-2) plays an important role in lung cancer pathogenesis. Celecoxib (CLX), a selective COX-2 inhibitor, may have beneficial effects in COVID-19-induced inflammatory storms. The current study aimed to develop carrier-free inhalable CLX microparticles by electrospraying as a dry powder formulation for inhalation (DPI). CLX microparticles were prepared through an electrospraying method using a suitable solvent mixture at two different drug concentrations. The obtained powders were characterized in terms of their morphology, solid state, dissolution behavior, and aerosolization performance. Electrosprayed particles obtained from the ethanol-acetone solvent mixture with a drug concentration of 3 % w/v exhibited the best in vitro aerosolization properties. The value of the fine particle fraction obtained for the engineered drug particles was 12-fold higher than that of the untreated CLX. When the concentration of CLX was increased, a remarkable reduction in FPF was obtained. The smallest median mass aerodynamic diameter was obtained from the electrosprayed CLX at a 3% concentration (2.82 µm) compared to 5% (3.25 µm) and untreated CLX (4.18 µm). DSC and FTIR experiments showed no change in drug crystallinity or structure of the prepared powders during the electrospraying process. The findings of this study suggest that electrospraying has potential applications in the preparation of DPI formulations." @default.
- W4381249229 created "2023-06-20" @default.
- W4381249229 creator A5013855858 @default.
- W4381249229 creator A5023571572 @default.
- W4381249229 creator A5027780257 @default.
- W4381249229 creator A5038930560 @default.
- W4381249229 creator A5043708378 @default.
- W4381249229 creator A5065872485 @default.
- W4381249229 creator A5092206570 @default.
- W4381249229 date "2023-06-17" @default.
- W4381249229 modified "2023-09-30" @default.
- W4381249229 title "Carrier-Free Inhalable Dry Microparticles of Celecoxib: Use of the Electrospraying Technique" @default.
- W4381249229 cites W1551442147 @default.
- W4381249229 cites W1974426621 @default.
- W4381249229 cites W1975132504 @default.
- W4381249229 cites W1976177532 @default.
- W4381249229 cites W1992445150 @default.
- W4381249229 cites W1998858236 @default.
- W4381249229 cites W2003899699 @default.
- W4381249229 cites W2010229174 @default.
- W4381249229 cites W2021064852 @default.
- W4381249229 cites W2036516719 @default.
- W4381249229 cites W2037230716 @default.
- W4381249229 cites W2041792004 @default.
- W4381249229 cites W2056932561 @default.
- W4381249229 cites W2071447152 @default.
- W4381249229 cites W2075488756 @default.
- W4381249229 cites W2079152061 @default.
- W4381249229 cites W2080287255 @default.
- W4381249229 cites W2080835752 @default.
- W4381249229 cites W2090620682 @default.
- W4381249229 cites W2112135623 @default.
- W4381249229 cites W2113118463 @default.
- W4381249229 cites W2118957675 @default.
- W4381249229 cites W2122801398 @default.
- W4381249229 cites W2124581619 @default.
- W4381249229 cites W2148982940 @default.
- W4381249229 cites W2153898590 @default.
- W4381249229 cites W2162818046 @default.
- W4381249229 cites W2169355562 @default.
- W4381249229 cites W2264633557 @default.
- W4381249229 cites W2288962493 @default.
- W4381249229 cites W2347064440 @default.
- W4381249229 cites W2619830614 @default.
- W4381249229 cites W2747910839 @default.
- W4381249229 cites W2751646851 @default.
- W4381249229 cites W2765194140 @default.
- W4381249229 cites W2765624753 @default.
- W4381249229 cites W2768806857 @default.
- W4381249229 cites W2797311865 @default.
- W4381249229 cites W2884214177 @default.
- W4381249229 cites W2896909187 @default.
- W4381249229 cites W2904441011 @default.
- W4381249229 cites W2920461546 @default.
- W4381249229 cites W2971708168 @default.
- W4381249229 cites W2996222126 @default.
- W4381249229 cites W3000629417 @default.
- W4381249229 cites W3011135651 @default.
- W4381249229 cites W3086451115 @default.
- W4381249229 cites W3089872517 @default.
- W4381249229 cites W3092181046 @default.
- W4381249229 cites W3094908355 @default.
- W4381249229 cites W3136216056 @default.
- W4381249229 cites W3139160139 @default.
- W4381249229 cites W3148007562 @default.
- W4381249229 cites W3185807305 @default.
- W4381249229 cites W3188348868 @default.
- W4381249229 cites W4210937361 @default.
- W4381249229 cites W4211014435 @default.
- W4381249229 cites W4280581322 @default.
- W4381249229 cites W4282914083 @default.
- W4381249229 cites W4283746494 @default.
- W4381249229 cites W4285388804 @default.
- W4381249229 cites W4295532938 @default.
- W4381249229 cites W4312210938 @default.
- W4381249229 cites W4327952680 @default.
- W4381249229 cites W4367048246 @default.
- W4381249229 cites W628236243 @default.
- W4381249229 cites W918899933 @default.
- W4381249229 doi "https://doi.org/10.3390/biomedicines11061747" @default.
- W4381249229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37371841" @default.
- W4381249229 hasPublicationYear "2023" @default.
- W4381249229 type Work @default.
- W4381249229 citedByCount "0" @default.
- W4381249229 crossrefType "journal-article" @default.
- W4381249229 hasAuthorship W4381249229A5013855858 @default.
- W4381249229 hasAuthorship W4381249229A5023571572 @default.
- W4381249229 hasAuthorship W4381249229A5027780257 @default.
- W4381249229 hasAuthorship W4381249229A5038930560 @default.
- W4381249229 hasAuthorship W4381249229A5043708378 @default.
- W4381249229 hasAuthorship W4381249229A5065872485 @default.
- W4381249229 hasAuthorship W4381249229A5092206570 @default.
- W4381249229 hasBestOaLocation W43812492291 @default.
- W4381249229 hasConcept C105702510 @default.
- W4381249229 hasConcept C126322002 @default.
- W4381249229 hasConcept C13245373 @default.
- W4381249229 hasConcept C13965031 @default.
- W4381249229 hasConcept C147789679 @default.